In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

Regeneron Pharmaceuticals Inc. closed 50.02% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00. The company’s shares closed last Friday at $1,042.69.